By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ophthotech Corporation 

One Penn Plaza, Suite 1924

New York  New York  10119  U.S.A.
Phone: 212-845-8200 Fax: 212-845-8250


Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden. For more information, please visit


One Penn Plaza
Suite 1924
New York, NY 10119
Phone (212) 845-8200
Fax (212) 845-8250

One University Square Drive
Suite 280
Princeton, NJ 08540
Phone (609) 945-6050
Fax (609) 452-7435

Key Statistics

Email: n/a
Ownership: Public

Web Site: Ophthotech Corporation
Symbol: OPHT

Company News
Ophthotech Corporation (OPHT) To Present At The LEERINK Partners 5th Annual Global Healthcare Conference 2/3/2016 11:58:53 AM
Ophthotech Corporation (OPHT) Announces First Patient Dosed In Zimura Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration 1/27/2016 10:01:48 AM
Ophthotech Corporation (OPHT) Announces Appointment Of David E. Redlick To Its Board Of Directors 1/7/2016 11:43:58 AM
Glenn P. Sblendorio To Join Ophthotech Corporation (OPHT) As Executive Vice President, Chief Operating Officer And Chief Financial Officer 1/5/2016 10:54:34 AM
Ophthotech Corporation (OPHT) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/5/2016 10:45:58 AM
Ophthotech Corporation (OPHT) To Present At The Oppenheimer 26th Annual Healthcare Conference 12/2/2015 10:45:03 AM
Ophthotech Corporation (OPHT) To Host R&D Investor Day On December 3, 2015 12/1/2015 10:23:05 AM
Ophthotech Corporation (OPHT) Announces That Genentech (RHHBY), A Roche (RHHBY) Wholly-Owned Subsidiary, Elects To Exercise Its Right To Opt-In To The Novartis Portion Of The Ophthotech / Novartis AG (NVS) Ex-US Agreement For Fovista® To Treat Wet Age-Related Macular Degeneration 11/17/2015 12:11:04 PM
Ophthotech Corporation (OPHT) To Present At The 2015 Stifel Healthcare Conference 11/12/2015 11:40:04 AM
Ophthotech Corporation (OPHT) Reports Third Quarter 2015 Financial And Operating Results 11/5/2015 12:52:58 PM